BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 19, 2019
View Archived Issues
IKK-alpha and BRAF kinases implicated in DNA damage response can be targeted in cancer
Read More
Integrin alphaVbeta6 found to be an effective target for pancreatic ductal adenocarcinoma therapy
Read More
TRPV1 as a novel therapeutic target in type 2 diabetes mellitus
Read More
GM1 ganglioside is protective in alpha-synuclein model of Parkinson's disease
Read More
Shanghai Yingli Pharmaceutical identifies TGF-beta receptor type-1 inhibitors
Read More
Oxford University Innovation discloses RAS-effector protein interaction inhibitors
Read More
Enhancement of neuronal M-Type K+ currents prevents brain damage following traumatic brain injury
Read More
Mitochondrial metabolism promotes proteasome inhibitor resistance and sensitivity to elesclomol
Read More
Redx Pharma presents Rho-associated protein kinase inhibitors
Read More
LEF1 overexpression implicated in esophageal squamous cell carcinoma via TGF-beta signaling
Read More
Neutrophil extracellular traps help gallstones form
Read More
NFKBIL1 gene polymorphisms linked to autistic-like traits
Read More
Fujimoto Pharmaceutical describes new TNF-alpha production inhibitors
Read More
Microbiome boosts host defense against chlamydia
Read More
Medscienta presents new antiatherosclerotic agents
Read More
FDA approves Rinvoq for the treatment of moderate to severe rheumatoid arthritis
Read More
FDA approves the first new treatment in nearly a decade for patients with myelofibrosis
Read More
Scancell provided update on phase II study of SCIB-1 in patients with advanced melanoma
Read More
Recruitment ongoing in Janssen's first-in-human study of JNJ-74699157
Read More
Patient recruitment initiated in phase II study of TQ-B3101 in ROS1-positive NSCLC
Read More
Bird Rock Bio initiates phase II study of nimacimab in patients with diabetic gastroparesis
Read More
Fulcrum Therapeutics initiates phase IIb ReDUX4 study of losmapimod in FSHD
Read More
